Globus Medical (GMED)vsMerck & Company Inc (MRK)
GMED
Globus Medical
$80.26
-1.42%
HEALTHCARE · Cap: $10.45B
MRK
Merck & Company Inc
$129.79
-0.44%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2021% more annual revenue ($65.77B vs $3.10B). GMED leads profitability with a 18.9% profit margin vs 13.6%. GMED appears more attractively valued with a PEG of 1.73. GMED earns a higher WallStSmart Score of 74/100 (B).
GMED
Strong Buy74
out of 100
Grade: B
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+35.9%
Fair Value
$137.63
Current Price
$80.26
$57.37 discount
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$129.79
$48.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 66.7% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.3%
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GMED
The strongest argument for GMED centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 18.9% and operating margin at 21.3%. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
GMED profiles as a growth stock while MRK is a value play — different risk/reward profiles.
GMED carries more volatility with a beta of 0.95 — expect wider price swings.
GMED is growing revenue faster at 27.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (74/100 vs 50/100), backed by strong 18.9% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?